99MTC-Ceftizoxzime scintigraphy in normal rats and abscess induced rats;Gammagrafía con 99mTc-ceftizoxima en ratas normales y en ratas con absceso inducido

Revista Espanola de Medicina Nuclear

Volumn 24, Issue 5, 2005, Pages 312-318

  Gomes Barreto, V ^a   Rabiller, G ^b   Iglesias, F ^b   Soroa, V ^b   Tubau, F ^a   Roca, M ^b   Martin Comin J ^b,c  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Hospital Universitario de Bellvitge IDIBELL   (Brazil)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

99mTc ceftizoxime; Animal model; Infection

Indexed keywords

TECHNETIUM 99M; ZYMOSAN; CEFTIZOXIME; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M CEFTIZOXIME; TECHNETIUM COMPLEX;

ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; BODY IMAGE; BONE INFECTION; CALCULATION; CONTROLLED STUDY; ESCHERICHIA COLI; HEART; KIDNEY; LIVER; LUNG; MEASUREMENT; MUSCLE CONTRACTION; NONHUMAN; RAT; SCANNING ELECTROCHEMICAL MICROSCOPY; SCINTIGRAPHY; SPLEEN; STAPHYLOCOCCUS AUREUS; ANIMAL; DIFFERENTIAL DIAGNOSIS; MICROBIOLOGY; SCINTISCANNING; SPRAGUE DAWLEY RAT;

ABSCESS; ANIMALS; CEFTIZOXIME; DIAGNOSIS, DIFFERENTIAL; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 28444433050     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079282     Document Type: Article

References (16)

1. Sculier JP, Weerts D, Klasters KYJ. Causes de death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. Eur J Cancer Clin Oncol. 1984;20:55-60.
2. Datz FL. The currents Status de radionuclide, infection imaging. En: Freeman LM, editor. Nuclear medicine annual. New York: Raven Press; 1993. p. 47-76.
3. Datz FL. Indium-111-labeled leucocytes for the detection de infection: currents status. Semin Nucl Med. 1994;24:92-109.
4. Becker W. The contribution de nuclear Medicine to the patient with infection. Eur J Nucl Med. 1995;22:1195-211.
5. Solanki KK, Bomanji J, Siraj Q, Small M, Britton KE. Tc-99m "Infecton". A new class de radiopharmaceutical for imaging infection. J Nucl Med. 1993;34:119P.
6. Britton KE, Vinjamuri S, Hall AV, Solanki KK, Siraj QH, Bomanji J, et al. Clinical evaluation de technetium-99m infect on for localization de bacterial infection. Eur J Nucl Med. 1997;24:553-6.
7. Britton KE, Wareham DW, Das SS, Solanki KK, Amaral H, Bhatnagar A, Katamihardja AH, Malamitsi J, Moustafa HM, Soroa VE, Sundram FX, Padhy AK. Imaging bacterial infection with (99m)Tc-ciprdeloxacin (Infecton). J Clin Pathol. 2002;55:817-23.
8. Sarda L, Cremieux AC, Lebellec Y, Meulemans A, Lebtahi R, Hayem G, Genin R, Delahaye N, Huten D, LeGuludec D. Inability de Tc-99m-cyprdeloxacin to discriminate between septic y sterile osteoarticular diseases. J Nucl Med. 2003;44:920-6.
9. Gomes Barreto V, Iglesias F, Roca M, Tubau F, Martín-Comín J. Marcaje de ceftizoxima con Tc-99m. Rev Esp Med Nucl. 2000;19:479-83.
10. Gomes Barreto V, Iglesias F, Roca M, Tubau F, Martín-Comin J. Biodistribution de the Tc-99m-ceftizoxime in animal model de infection y inflammation. Eur J Nucl Med. 2000;27:970.
11. Fischman AJ, Babich JW, Rubin RH. Infection imaging with tecnethium-99m-labeled chemetactic peptide analogs. Sem Nucl Med. 1994;24:154-68.
12. Van der Laken CJ, Boerman OC, Oyen WJG, Van der Vem, et al. The kinetics de radiolabeled interleukin-8 in infection y sterile inflammation. Nuclear Medicine Communications. 1998;19:271-81.
13. Singh AK, Verma J, Bhatnagar A, Ali A. Tc-99m-labeled sparfloxacin: a specific infection imaging agent. WJNM. 2003;2:103-9.
14. Chacko TK, Zhuang H, Nakhoda KZ, Moussavian B, Alavi A. Applications de FDG positron emission tomography in the diagnosis de infection. Nucl Med Commun. 2003;24:615-24.
15. st Century. Braz Arch Biol Technol. 2002;45:25-37.
16. De Winter F, Van de Wiele C, Dumont F, Solanki K, Britton KE, Slegers G, Dierckx RA, Thierens H. Biodistribution y dosimetry de Tc-99m-cyprdeloxacin, a promising agent for the diagnosis de bacterial infection. Eur J Nucl Med. 2001;28:570-4.